pH-responsive Oleic Acid based nanocarriers: melanoma treatment strategies

Author(s):  
Federica Rinaldi ◽  
Jacopo Forte ◽  
Giada Pontecorvi ◽  
Patrizia Nadia Hanieh ◽  
Alessandra Carè ◽  
...  
Author(s):  
Mengqi Guan ◽  
Shoujun Zhu ◽  
Shanshan Li

Melanoma is an aggressive type of skin cancer with increasing incidence and high mortality rates worldwide. However, there is still a lack of efficient and resolutive treatment strategies, particularly in clinical settings. Currently, nanomedicine, an emerging area in the medical field, is being widely investigated in small animal models to afford melanoma theranostics. However, several problems, such as tumor heterogeneity, and drug resistance treatment with a single therapy, remain unresolved. Previous reviews have primarily focused on monotherapy for melanoma in the context of nanomedicine. In this review article, we summarize the recent progress in the application of nanomedicine for melanoma treatment, with particular attention to combination therapy based on nanomedicine to achieve optimized therapeutic output for melanoma treatment. In addition, we also highlight the fluorescence-guided strategies for intraoperative melanoma detection, especially in the near-infrared imaging window with greatly improved imaging contrast and penetration depth.


2010 ◽  
Vol 130 (12) ◽  
pp. 2699-2701 ◽  
Author(s):  
Michele B. Weiss ◽  
Andrew E. Aplin

2015 ◽  
Vol 38 (3) ◽  
pp. E6 ◽  
Author(s):  
James P. Caruso ◽  
Or Cohen-Inbar ◽  
Mark H. Bilsky ◽  
Peter C. Gerszten ◽  
Jason P. Sheehan

The management of metastatic spinal melanoma involves maximizing local control, preventing recurrence, and minimizing treatment-associated toxicity and spinal cord damage. Additionally, therapeutic measures should promote mechanical stability, facilitate rehabilitation, and promote quality of life. These objectives prove difficult to achieve given melanoma's elusive nature, radioresistant and chemoresistant histology, vascular character, and tendency for rapid and early metastasis. Different therapeutic modalities exist for metastatic spinal melanoma treatment, including resection (definitive, debulking, or stabilization procedures), stereotactic radiosurgery, and immunotherapeutic techniques, but no single treatment modality has proven fully effective. The authors present a conceptual overview and critique of these techniques, assessing their effectiveness, separately and combined, in the treatment of metastatic spinal melanoma. They provide an up-to-date guide for multidisciplinary treatment strategies. Protocols that incorporate specific, goal-defined surgery, immunotherapy, and stereotactic radiosurgery would be beneficial in efforts to maximize local control and minimize toxicity.


Nanoscale ◽  
2021 ◽  
Author(s):  
Junmin Lee ◽  
Yonggang Wang ◽  
Chengbin Xue ◽  
Yi Chen ◽  
Moyuan Qu ◽  
...  

Injectable shear-thinning biomaterials (STBs) have attracted significant attention because of their efficient and localized delivery of cells as well as various molecules ranging from growth factors to drugs. Recently, electrostatic...


Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1007 ◽  
Author(s):  
Anouk Jochems ◽  
Monique K. van der Kooij ◽  
Marta Fiocco ◽  
Maartje G. Schouwenburg ◽  
Maureen J. Aarts ◽  
...  

Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07–4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.


2020 ◽  
Vol 109 (8) ◽  
pp. 2594-2606
Author(s):  
Sifiso S. Makhathini ◽  
Calvin A. Omolo ◽  
Ramesh Gannimani ◽  
Chunderika Mocktar ◽  
Thirumala Govender

2014 ◽  
Vol 35 (2) ◽  
pp. 293-300 ◽  
Author(s):  
Xiaobo Shu ◽  
Yingfeng Meng ◽  
Liping Wan ◽  
Gao Li ◽  
Mou Yang ◽  
...  

2018 ◽  
Vol 550 (1-2) ◽  
pp. 149-159 ◽  
Author(s):  
Danford Mhule ◽  
Rahul S. Kalhapure ◽  
Mahantesh Jadhav ◽  
Calvin A. Omolo ◽  
Sanjeev Rambharose ◽  
...  
Keyword(s):  

2007 ◽  
Vol 310 (1) ◽  
pp. 260-269 ◽  
Author(s):  
Qiang Lan ◽  
Chao Liu ◽  
Fei Yang ◽  
Shangying Liu ◽  
Jian Xu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document